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1. Introduction  
There are extensive epidemiological data demonstrating that high blood cholesterol levels 
increase cardiovascular risk, and that this risk is dependent on the levels of the different 
blood cholesterol fractions. Moreover, the reduction of total blood cholesterol has been 
clearly related to a reduction in the risk of stroke, coronary disease and overall 
cardiovascular death. However, the traditional cholesterol measurements tend to be most 
accurate at predicting risk for those at the lower and higher ends of the risk spectrum. 
Recent data has shown LDL-Cholesterol/HDL-Cholesterol ratio and even Total-
Cholesterol/HDL-Cholesterol ratio, to be accurate predictors of cardiovascular risk. In fact, 
changes in ratios have been shown to be better indicators of successful CHD risk reduction 
than changes in absolute levels of lipids or lipoproteins. In the Helsinki Study, the LDL-
C/HDL-C ratio had more prognostic value than LDL-C or HDL-C alone (Manninen, 
Tenkanen, Koskinen et al, 1992). The ratio was especially accurate at predicting risk among 
those who also had elevated triglyceride levels. The PROSPER trial, a retrospective analysis 
of 6,000 patients, found that the ratio of LDL-C/HDL-C was the most powerful measure of 
cardiovascular disease risk in elderly people (Packard, Ford, Robertson et al, 2005). The 
PROCAM Study, which included almost 11,000 men aged 36 to 65 who were studied for 4 to 
14 years, found a continuous and graded relationship between the LDL-C/HDL-C ratio and 
CVD mortality (Cullen, Schulte, Assmann et al, 1997). In addition, comparison of individual 
LDL-C/HDL-C ratios from subjects in the Framingham Study clearly indicates that these 
ratios are significantly more robust predictors of CVD than the individual levels of LDL-C 
or HDL-C (Kannel, 2005). 
2. Theoretical framework 
2.1 Cardiovascular risk – Generalities 
Cardiovascular diseases are an unavoidable topic when discussing health related issues, 
particularly in developed societies. Cardiovascular disease is the leading cause of mortality 
in these countries (World Health Organization, 2002), assuming a progressively more 
important role in developing countries and even in less developed countries. In the latter, 
we may consider the presence of a double-frontier of health risk. These countries show 
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coexistence of important mortality indexes related to diseases whose prevalence is a 
demonstration to their stage of development (perinatal, nutritional and infectious health 
problems), with a more consistent presence of coronary disease, with increased percentage 
reaching 137% for males and 120% for females by the year 2010 (Yusuf, Reddy, Ounpuu et 
al, 2001). 
In epidemiological terms, coronary heart disease and cerebrovascular disease represent the 
most significant expressions of cardiovascular disease, and were the main causes of 
mortality and morbidity worldwide, accounting for one third of total mortality in the year 
2001 (American Heart Association, 2003). According to the World Health Organization, 
every year 16 million deaths occur from cardiovascular disease, and this number is expected 
to rise to 20 million in the first decade of the XXI century (World Health Organization, 2002). 
The singular importance of coronary heart disease is extraordinarily important and it is 
estimated that mortality by this disease had risen to 7.2 million individuals by the year 2001 
(World Health Organization, 2002). However, in recent years, there has been a trend 
towards a decline in this disease in Western countries, with a concomitant increase in other 
lands, notably in Russia and Eastern European countries. In fact, in Western countries, the 
number of deaths from coronary per 100,000 inhabitants was 151 in 1972, dropping to 44 in 
2004, in men aged 64 or less. Similar reductions were also observed in females (36 to 11 
women per 100,000). Paradoxically, in Russia, there was a marked increase of this rate, from 
169/100.000, in the year 1980, to 242/100.000 deaths, in the year 2005 (Allender, 
Scarborough, Black et al, 2008). 
The onset of cardiovascular disease is consistently related to the presence of a group of 
cardiovascular risk factors, whose manipulation can be crucial to its prevention (see Table 1). 
 
Reversible 
   Smoking 
   Arterial hypertension 
   Hyperlipidemia 
   Obesity 
   Sedentarism 
   Alcohol 
   Stress 
Irreversible 
   Family history 
   Male gender 
   Age 
Partially Reversible 
   Diabetes 
   Menopause 
Table 1. Conventional cardiovascular risk factors. 
Concerning reversible risk factors in which intervention could be decisive, we  
should highlight the relative importance of smoking, arterial hypertension and 
hypercholesterolaemia. Although the global fight against all reversible risk factors constitute 
a therapeutic imperative, the elimination of hypercholesterolemia would result in the single 
most important benefit against the incidence of coronary heart disease as well as other 
atherosclerotic vascular problems (Wilson, D'Augustine, Levy et al, 1998). 
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Regarding arterial hypertension, it always presents itself as a major risk factor, given its very 
high incidence and prevalence. Despite all the research carried out and considering all the 
remarkable therapeutic advances, the control of blood pressure levels only provides a 
reduction of about 40% in mortality from cerebrovascular disease and a more modest 20% 
reduction in mortality from coronary heart disease (Kaplan, 2002).  
Diabetes is another important risk factor, with the particularity of becaming the major 
epidemy of this century given its substantial and consistent epidemiological growth. The 
high cardiovascular risk that diabetes provides is well illustrated by the prognostic 
similarity between a diabetic patient without clinical manifestations of coronary heart 
disease and a patient with a history of acute coronary events (Hafnner, Lethe, Ronnema et al, 
1988).  
Obesity is undoubtedly a major risk factor for cardiovascular disease (Higgins, Kannel, 
Garrison et al, 1988), now becoming a public health problem, given the alarming increase of 
its prevalence in industrialized countries. The pathogenic mechanisms involved in this 
situation are complex and not just related to the metabolic overload involved, but also 
determined by its close associations with arterial hypertension, type 2 diabetes, 
dyslipidemia, and inflammation (Higgins, Kannel, Garrison et al, 1988). 
Smoking is consensually assumed as a relevant contributer to cardiovascular disease, both 
in the active as well as the passive form. Some studies indicate that smokers have a 
reduced life expectancy of about ten years (although this number is dose-dependent) and 
that this habit cancells the natural cardioprotection in women (Silva, 2000). In fact, the 
differences in cardiovascular risk amongst men and women are well known, largely 
documented by the classic time lag between genders, with a higher risk in males until the 
fifth decade of life, with a progressive increase in women of cardiovascular risk until the 
eighth decade of life, when the risk is similar in men and women. The explanation for this 
is closely linked to the production and subsequent estrogen deficiency (as a consequence 
of menopause) seen in different phases of a woman’s life. But other factors must not be 
overlooked. For instance, If we consider only the lipid profile changes induced by 
menopause, on average a 10% increase in LDL-cholesterol, an 8% reduction in HDL-
cholesterol and an elevation in triglycerides are expected. Nonetheless, these changes can 
be normalized by hormonal replacement therapy (Stampfer, Colditz, Willet et al, 1991). 
Oral contraception, by contrast, tends to cause an adverse impact on lipid profile. At 
present, the worrying rate of young women with acute coronary events, a situation rarely 
seen before, has directed special attention to factors that could be blamed for this 
surprising finding. The association of hormonal contraception with smoking has emerged 
as very common in this population, likely to concur not only for atherogenic metabolic 
features but also for potentially thrombotic coagulation disorders (Mosca, Grundy, 
Judelson et al, 1999). 
The cardiovascular impact of alcohollic intake must also be considered. The cardiovascular 
impact of this behaviour is closely related to the amount of alcohol consumed. A moderate 
intake may confer some cardiovascular protection, particularly by raising HDL-cholesterol 
and reducing platelet aggregation, yet it may lead to a higher incidence of arterial 
hypertension and cerebrovascular disease. Patterns of high alcoholic consumption are an 
unusually hazardous behaviour, particularly for the heart, greatly increasing the risk of 
sudden death (Silva, 2000). 
www.intechopen.com
 
Dyslipidemia - From Prevention to Treatment 
 
282 
2.2 Cardiovascular risk – Dislipidemia 
Lipids are a very heterogeneous group of compounds, and their influence on metabolism 
goes far beyond the misdeeds attributed to him. Lipids constitute an important source of 
energy storage, represented by triglycerides, and assume a great importance in the 
constitution of the brain (17% of its dry weight), the formation of hormones, lipoproteins, 
bile acids, vitamins, and in the structure of cell membranes. Cholesterol and Triglycerides 
are transported between various components of the organism by specific proteins called 
apoproteins. These constitute the protein fraction of lipoproteins whose lipid component 
includes phospholipids, cholesterol and Triglycerides. Lipoproteins are usually divided into 
six classes according to their composition, size, density and function: Quilomicra, VLDL 
(very low density lipoproteins), IDL (intermediate density lipoprotein), LDL (low density 
lipoprotein), HDL (high density lipoprotein) and Lipoprotein (a). The interaction of 
lipoproteins with a high number of enzymes, transport proteins and receptors, constitutes a 
complex metabolism where equilibrium is determined by intrinsic and extrinsic factors, and 
its unbalance leads to the pathophysiological cascade of atherosclerosis, with its well known 
clinical consequences (Silva, 2000). In very one-dimensional terms, fat from the diet is 
transported to the intestinal wall and integrated into large lipoprotein particles rich in 
triglycerides - the Quilomicra - which, when secreted by the lymphatic system eventually 
reach the bloodstream. The liver, in its turn, synthesizes other lipoproteins with high 
content of triglycerides, the VLDL. The extracellular lipoprotein-lipase degrades 
triglycerides of Quilomicra and VLDL into free fatty acids, which are deposited in tissues. 
Lipoproteins, by reducing their concentration in triglycerides, are converted into IDL, which 
are usually hydrolyzed by the hepatic lipase, and are than converted into LDL, which bind 
to specific liver or peripheral receptors. Meanwhile, in another cycle - the reverse transport 
of cholesterol - HDL particles pick up cholesterol deposited in the arterial wall and provide 
transportation to the liver, where it is subsequently excreted in the bile (Eckardstein, 
Hersberger & Roher, 2005). 
The disorder of lipid metabolism is a key player for the occurrence of cardiovascular disease 
and particularly heart disease. For many years, cholesterol has been directly related to 
cardiovascular prognosis. This relationship is very consistent, as an increase of 2 to 3% in the 
incidence of coronary heart disease is expected for every 1% increase in total cholesterol 
(Carlson, Bottiger & Ahfeldt, 1979). A review of internationally published studies showed, 
however, that this association may be even stronger. Thus, a 10% increase in total 
cholesterol relates to a 38% increase in the risk of coronary-related mortality (Law, Wald & 
Thompson, 1994). More recently, several clinical studies on the primary and secondary 
prevention of coronary heart disease emphasized the importance of the LDL fraction (ILIB 
International Lipid Information Bureau, 2003) allowing the potential for the discrimination 
of cardiovascular risk. In fact, the risk of each patient may best be defined by the magnitude 
of the LDL-cholesterol rather than its total cholesterol, which is why international standards 
for the treatment of dyslipidemia have been oriented to listing the risk thresholds and 
treatment goals depending on the plasma levels of this lipoprotein. In practical terms, the 
determination of LDL-cholesterol may be derived by the Friedewald formula, where LDL 
Cholesterol = Total Cholesterol - HDL Cholesterol - VLDL cholesterol, VLDL cholesterol are 
derived from triglycerides/5. 
For many years it was difficult to classify unequivocally Triglycerides as an independent 
risk factor for the occurrence of coronary heart disease, a situation presumably related to the 
wide fluctuations observed in their concentrations throughout the day, with the 
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heterogeneity of triglyceride-rich lipoproteins (Quilomicra and VLDL) and its inseparable 
association with other risk factors. However, several studies have demonstrated a clear 
correlation between their levels and the occurrence of coronary heart disease, indicating that 
the presence of high levels of Triglycerides leads to a 13% increase in the risk of 
cardiovascular disease in men and 37% in women (Castelli, 1986; Criqui, Heiss, Cohn et al, 
1993; Hokanson & Austin, 1996; Assman, Schulte & von Eckardstein, 1996). With regard to 
HDL-cholesterol, its inverse relationship with the risk of coronary heart disease is well 
accepted. In fact, this risk is 2 to 3% lower for each 1mg/dl elevation of HDL-Cholesterol 
(Gordon, Probstfiel, Garrison et al, 1989). The protective properties of this fraction derive not 
only from its involvement in reverse cholesterol transport, but are also a consequence of its 
anti-inflammatory capacity and protection against LDL-cholesterol oxidation (Ansell, 
Navab, Watson et al, 2004). On the other hand, it is recognized that individuals with very 
low levels of HDL-cholesterol have a higher cardiovascular risk. This population is often 
characterized for having concomitant hypertriglyceridemia, obesity, a sedentary lifestyle, 
active tobacco intoxication and decreased glucose tolerance (World Health Organization, 
1999). In fact, an increased occurrence of cardiovascular events is expected for levels of 
HDL-cholesterol below 40 mg/dl (1.0 mmol/L) in men and less than 46 mg/dl (1.2 
mmol/L) in women (UK HDL-C Consensus Group, 2004). 
Recent evidence further stresses the importance of determining the non-HDL-cholesterol, 
defined by the concentration of LDL-cholesterol + VLDL-cholesterol. This parameter can 
better translate the risk of cardiovascular mortality than LDL-cholesterol, as it expresses 
more accurately the lipoprotein atherogenicity (Cui, Blumenthal, Flaws et al, 2001). 
In recent years, a large number of risk factors for vascular disease have emerged from the 
international literature (see Table 2), demonstrating the relevance of more complex lipid 
disorders for the pathophysiology of atherosclerosis. Other emerging risk factors are related 
to inflammatory markers, as well as by the presence of metabolic changes, subtle changes in 
coagulation, hormonal disturbances and psychological or behavioral disorders (ILIB 
International Lipid Information Bureau, 2003). 
 
Lipidic 
   Lipoproteic remnants 
   Lipoprotein (a) 
   Small and dense LDL 
   HDL subspecies 
   apolipoprotein B 
   Apolipoprotein A-1 
Inflammatory 
   High-sensitivity CRP 
   Homocysteine 
   Interleukin-6 
   Cell adhesion molecule-1  
   Selectin-CD40 
Metabolic 
   Postprandial hyperinsulinemia   
   (insulin resistance) 
Coagulation 
   Fibrinogen 
   Von Willebrand Factor 
   Factor VII 
   Plasminogen activator inhibitor (PAI-1) 
 
Psychological / Behavioral 
   Alcoholism 
   Depression 
   Social Isolation 
   Loss and social support 
   Low socioeconomic status 
Hormonal 
   Loss of estrogen production (menopause) 
Table 2. Emerging cardiovascular risk factors. 
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As we have seen, each stated factor conveys a certain risk to the affected population. 
However, in everyday clinical practice a large majority of patients have associations of these 
factors and, as such, have cardiovascular risks that express the magnitude of individual risk 
factors present in an exponential, rather than additive, trend (Yusuf, Giles, Croft et al, 1998; 
American Heart Association, 2002). 
An alternative option, with very promising results in the context of cardiovascular risk 
stratification and assessment of the effectiveness of lipid-lowering interventions, is the use 
of lipid ratios, just as the LDL-Cholesterol/HDL-Cholesterol ratio and the Total-
Cholesterol/HDL-Cholesterol ratio, which have the added advantage of being easy to use in 
clinical practice (Gotto, Whitney & Stein, 2000). Changes in these relations have in fact been 
shown to better indicate the reduction in cardiovascular risk compared with the absolute 
levels of conventionally used lipid measures (Natarajan, Glick, Criqui et al, 2003; Kannel, 
2005). On the other hand, the estimated LDL-Cholesterol/HDL-Cholesterol ratio translates, 
albeit imperfectly, an approach to the relationship of plasma apolipoproteins (apo) A-1 and 
apo B (Walldius & Jungner, 2005), thus enriching the lipid characterization of each patient, 
with the possibility of a better discrimination of cardiovascular risk, particularly among 
groups at intermediate cardiovascular risk (Gotto, Whitney, Stein et al, 2000). 
Several large studies have demonstrated that the LDL-Cholesterol/HDL-Cholesterol ratio is 
an excellent predictor of risk of coronary disease and an excellent way to monitor the impact of 
lipid-lowering therapies (Manninen, Tenkanen, Koskinen et al, 1992; Kannel, 2005; Cullen, 
Schulte, Assmann et al, 1997; Stampfer, Sacks, Salvini et al, 1991; Gaziano, Hennekens, 
O'Donnell et al, 1997). In the Helsinki Study, a clinical trial with a 5-year follow-up, involving 
more than 4000 middle-aged men with hyperlipidemia, the LDL-Cholesterol/HDL-
Cholesterol ratio had a superior prognostic value compared with isolated values of LDL-
Cholesterol and HDL-Cholesterol. The predictive ability of this ratio was particularly strong in 
patients with concomitant elevation of triglycerides. It was further shown that the LDL-
Cholesterol/HDL-Cholesterol ratio together with the fasting triglyceride concentration, 
allowed the identification of a particular subgroup of patients that had a remarkable 70% 
reduction in the risk of coronary heart disease with gemfibrozil (lipid-lowering agent) therapy. 
In the PROSPER trial, a retrospective analysis of 6,000 patients, the LDL-Cholesterol/HDL-
Cholesterol ratio was the stronger predictor of cardiovascular events in elderly patients 
(Packard, Ford, Robertson et al, 2005). From this study has emerged the recommendation of 
pharmacological intervention whenever the LDL-Cholesterol/HDL-Cholesterol ratio values 
exceed 3.3 units. Another study (PROCAM study) involving about 11,000 men aged between 
36 and 65, followed over 4 to 14 years, has documented an extremely important and linear 
relationship between the LDL-Cholesterol/HDL-Cholesterol ratio and cardiovascular 
mortality (Cullen, Schulte, Assmann et al, 1997). In this study, cardiovascular mortality peaked 
for LDL-Cholesterol/HDL-Cholesterol values between 3.7 and 4.3 units. In line with these 
results is the Physician's Health Study, involving 15,000 men (40 to 84 years), where there was 
a 53% increase in the risk of an acute coronary event for each one-unit increase in the LDL-
Cholesterol/HDL-Cholesterol ratio (Stampfer, Sacks, Salvini et al, 1991). In another mixed 
study, involving men and women under the age of 76, the LDL-Cholesterol/HDL-Cholesterol 
ratio showed a strong relationship with the risk of coronary events (Gaziano, Hennekens, 
O'Donnell et al, 1997), aspect reinforced in an analysis of patients from the Framingham Heart 
Study, where a clear superiority of LDL-Cholesterol/HDL-Cholesterol ratio in predicting 
cardiovascular events compared to the levels of isolated LDL-cholesterol and HDL-cholesterol 
was depicted (Kannel, 2005). 
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Another point that reinforces the superiority of the lipid ratios in the stratification of 
cardiovascular risk arises from the effect of dietary cholesterol on plasma lipid levels. 
Several studies have demonstrated that these ratios are not affected by dietary cholesterol 
(Greene, Zerner, Wood et al, 2005; Herron, Vega-Lopez, Earl et al, 2002). On the contrary, 
some studies have shown that dietary cholesterol interferes with LDL-cholesterol and HDL-
cholesterol, with little variation in the ratio (McNamara, 2000). On average, the predicted 
change in the LDL-Cholesterol/HDL-Cholesterol ratio per 100 milligrams/day increase in 
dietary cholesterol is quite small, around 0.01 (McNamara, 2000). 
2.3 Cardiovascular risk – Atherogenesis 
To understand the sequence of events that occur at the vascular level, resulting in 
devastating clinical manifestations that are all too familiar, we must look a little closer at the 
physiology of this system. 
One of the most important organs we have without doubt is the vascular endothelium. The 
endothelium is the inner portion of our vessels, which can be compared to a thin membrane 
that carpets the blood vessels, and its integrity is fundamental for the maintenance of several 
potentially unstable equilibria. In this sense, a huge amount of vascular wall or circulating 
factors are present in close relation to the endothelium, endlessly alternating between defense 
and aggression, aggression, with Nitric Oxide as the key protector. As the most egregious 
examples of interaction near the endothelium vicinity, we have the following associations: 
vasodilation/vasoconstriction; anti-trombotic/pro-trombotic; anti-inflamatory/pro-inflamatory, 
among others. The relative hegemony of each of these interacting factors will determine the 
final maintenance of endothelial integrity or, conversely, its dysfunction and destruction 
(Houston, 2002). Endothelial dysfunction is thus the initial phase of a cascade of events that 
flow until the onset of clinically overt disease. In a very simplified overview, once the 
endothelial barrier is compromised, an association of events takes place, mainly with a lipid 
flooding process of the vascular wall, with the mobilization of inflammatory cells, the 
expression of chemotactic factors, growth and proliferation of smooth muscle and 
connective tissue, among others. The histologic consequence of these processes ranges from 
an initial lipid streak that evolves for an atherosclerotic plaque that may progress to 
calcification, progressively reducing the vascular lumen (Silva, 2000). 
Curiously, most clinical cases are not determined directly by the extreme portion of the 
atherosclerotic continuum. In other words, cardiovascular events do not usually stem from 
progressive and insidious arterial occlusion, with consequent ischemia of downstream 
areas. Of course, cardiovascular events tend to be characterized by their acute nature, that is, 
by their sudden and unpredictable occurrence. As such, the implicit pathophysiology 
should express facts that support real-life events. In fact, one of the most important factors 
in the emergence of cardiovascular events is related to the so-called "atherosclerotic plaque 
stability". Thus, plaques with a small lipid core, with small inflammation infiltrate, and 
fitted with a thick, tough outer layer will be less susceptible to disruption by various 
harmful factors, such as blood pressure, sympathetic activity and other vasoconstrictor 
stimuli. In contrast, plaques with a rich lipid core, inflammatory activity and a significant 
weak fibrous cap will present a higher risk of fracture and exposure of their internal 
contents (Ridolfi & Hutchins, 1977). This in turn will lead to the activation of several factors 
that promote clotting and platelet aggregation in-sito (Falk, 1991), which may also lead to a 
sudden reduction of the vascular lumen, or even its complete occlusion by thrombosis. 
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Thus, the atherosclerotic process brings with it a wide array of metabolic, inflammatory and 
coagulation phenomena, decisively contributing to its clinical expression. Herein lies the 
justification of the diverse therapeutic targets that aimed for in these patients. 
The importance of hypercholesterolemia as a key-player in this cascade of events is 
unquestioned and widely demonstrated in the published literature. A perfect expression of 
the interaction between research and practice is surely the publication of recommendations 
and guidelines that assist clinicians in the rationalization of therapeutic means available. 
These emerge as regular updates of successive collections of published scientific data, 
outlined in an admirably succinct way so they can be strategically combined and applied to 
the most varied health systems worldwide. Regarding the core topic of this paper, we have 
to address the most relevant recommendations published by the European Society  
of Cardiology and the National Cholesterol Education Program (NCEP). These 
recomendations were prepared according to an individual-risk perspective, and the 
therapeutic goals are defined according to the expected individual risk at long-term. Table 3 
sumarizes the NCEP guidelines, revealing a clear therapeutic aggressiveness increase based 
on individual risk, as well as the adoption of progressively reduced target LDL-cholesterol 
values. 
 
 Target Therapeutic options 
High risk 
10-year risk> 20% 
Established 
cardiovascular 
disease 
Equivalents of 
Cardiovascular 
Disease 
 
LDL<100 mg/dl 
 
LDL<100 mg/dl-129 
mg/dl 
Dietary intervention
Drug treatment? 
 
LDL≥130 mg/dl 
Dietary intervention 
Drug treatment 
Intermediate risk 
≥ 2 Risk Factors 
10-year risk ≤ 20% 
 
 
10-year risk ≤ 10% 
 
LDL<130 mg/dl 
 
 
 
LDL<130 mg/dl 
 
LDL≥130 mg/dl 
Dietary intervention
Drug treatment 
 
LDL 130-160 mg/dl 
Dietary intervention
 
 
 
 
LDL≥160 mg/dl 
Dietary intervention 
Drug treatment 
Low risk 
10-year risk ≤ 10% 
≤ 1 risk factor 
LDL<160 mg/dl LDL 160-190 mg/dl 
Dietary intervention
Drug treatment? 
LDL≥190 mg/dl 
Dietary intervention 
Drug treatment 
Table 3. Hypercholesterolemia treatment algorithm of the second Report of the Third 
National Cholesterol Education Program – NCEP (2001). 
These recommendations also included some secondary therapeutic goals, including the 
attempt to reduce non-HDL cholesterol in patients with triglycerides above 200 mg/dl for 
values 30 mg/dL higher than the individual target for LDL-cholesterol. Another objective 
lies in promoting an increase in HDL-cholesterol. Although these objectives are based on a 
very interventionist philosophy, recent studies may impose additional requirements on 
these recommendations. In fact, the Heart Protection Study (Heart Protection Study 
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Collaborative Group, 2002) showed that a reduction of 30% compared to the more restrictive 
goal (LDL cholesterol <100 mg/dl) was related to an additional 30% reduction in the 
relative risk of coronary heart disease. The PROVE IT study (Cannon, Braunwald, McCabe 
et al, 2004), enrolled patients who had had acute coronary events and showed that larger 
reductions of LDL-cholesterol, to levels lower than 100 mg/dl, could significantly provide 
aditional benefit in terms of future cardiovascular mortality and morbidity. 
According to these results one has to consider more challenging treatment goals. The aim is 
to reach values of LDL-cholesterol <70mg/dl in patients with very high cardiovascular risk, 
such as those combining several primary risk factors (with primary relevance for diabetics), 
in patients with primary risk factors that are poorly controlled (with special care to the ones 
that maintain smoking habits), in patients with multiple risk factors of the so-called 
metabolic syndrome (triglycerides ≥ 200 mg/dl, non-HDL-cholesterol> 130 mg/dl, HDL-
cholesterol<40 mg/dl) and in patients with history of acute coronary events. 
The establishment of a therapeutic basis grounded in the control of cardiovascular risk 
factors has demonstrated its strong validity, and is further reinforced for its effectiveness in 
terms of cost-benefit. Improved control of risk factors almost certainly contributed to the 
50% reduction in cardiovascular mortality observed in the United States of America 
between 1980 and 1990, with 43% attributable to the verified pharmacological advances 
(Hunink, Glodman, Tosteson et al, 1997). In the Netherlands, similar results were observed, 
and primary prevention was responsible for a 40% decline in mortality from coronary heart 
disease between 1978 and 1985 (Grobee & Bots, 1996). The adoption of dietary measures in 
Finland, relying on an increase in the consumption of fruits and vegetables and a reduction 
of saturated fats intake, has resulted in a 65% reduction in mortality from coronary heart 
disease in a time horizon of 20 years (Pekka, Pirjo & Ulla, 2002). 
Despite the promising results indicated by these data, only 35% of Americans with a formal 
indication for dietary or pharmacological therapy, according to the recommendations of the 
NCEP (2001), are complying with it (Hoerger, Bala, Bray et al, 1988). In Canada, a study 
carried out between 1988 and 1993, including patients at high cardiovascular risk admitted 
to hospitals, showed very low percentages in relation to lipid dosing prescription (28%) and 
early dietary (22%) or pharmacological (8%) therapy (The Clinical Quality Improvement 
Network (CQIN) Investigators, 1995). 
In Europe, results have fallen below expectations. An important follow-up study - 
EUROASPIRE - between 1995 and 1996, envolving nine European countries, showed that 
86% of the enrolled patients had hypercholesterolaemia. Nevertheless, only 32% were on 
medication, and among those treated only 21% had achieved the target lipid levels 
(EUROASPIRE Study Group, 1997; EUROASPIRE I and II Group, 2001). 
In Asia and the Pacific, the outlook is not encouraging either. In patients hospitalized for 
acute coronary events, quite small rates of lipid profile dosing (1 to 58%) were observed, as 
well as for the prescription of diet (1 to 32%) or pharmacological (6 to 60%) therapy to 
patients with high Cholesterol levels (Asian-Pacific CHD Risk Factor Collaborative Group, 
1998). 
The control of risk factors in clinical practice is thus a vaguely realized desideratum. The 
EUROASPIRE study has clarified some trends from 1995 to 2000. If the positive results have 
raised expectations, with an improvement seen in the control of hypercholesterolemia and 
hypertension, they are still accompanied by other rather disappointing indicators, such as 
those of smoking habits, obesity and diabetes, whose prevalence has been steadily 
increasing (EUROASPIRE Study Group, 1997; EUROASPIRE I and Group II, 2001). In the 
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United States of America the results are also somewhat disappointing. In survivors of acute 
myocardial infarction or stroke, the control percentages for some primary risk factors are 
below expectations, particularly for smoking habits (18%), control of hypercholesterolemia 
(46%), diabetes (48%) and hypertension (53%) (Qureshi et al, 2001).  
As in almost all chronic conditions, the real picture lags far behind the expectations and 
available resources. Regarding hypercholesterolemia, the current situation is even less 
understandable, given its clear and strong association with the prevailing causes of death 
and incapacity, and the public awareness of the problem and in consideration of the 
demonstrated effectiveness of the available lipid-lowering drugs, that may have a quite 
favorable impact upon the prognosis of patients. 
3. Original research data 
3.1 Aim 
Given the demonstrated role-playing of blood cholesterol in the atherosclerotic continuum, 
we designed two studies to ascertain the usefulness of the LDL-cholesterol/HDL-
cholesterol, Triglycerides/HDL-cholesterol and Total-cholesterol/HDL-cholesterol ratios in 
predicting cardiovascular risk, through its relation to cardiovascular events and peripheral 
arterial disease (PAD) in two different clinical and experimental settings. 
3.2 Study 1 – Usefulness of the lipidic ratios predicting peripheral artery disease in 
hypertensive patients: A retrospective analysis 
The importance of the lipidic profile is well established in atherosclerotic processes related 
to coronary artery disease. Its relation with atherosclerosis in other vascular territories, 
particularly the inferior limbs has also received strong support from several experimental 
settings and in different clinical contexts. In order to address wether the lipid ratios can 
predict the occurrence of obstructive peripheral artery disease (PAD) we conducted a cross-
sectional study in a sample of hypertensive patients. The study population consisted of 920 
Portuguese nationals, aged between 20 and 91 years (mean 64.23 + 12.30 years). 
3.2.1 Methods 
A total of 920 hypertensive patients (51.3% female, age 64.22 ± 12.01 years) were 
consecutively included in the study. None of the patients were taking drugs or were in 
situations known to affect lipoprotein metabolism. Total cholesterol, triglycerides and HDL 
cholesterol were measured. LDL cholesterol was obtained by Friedewald’s formula  
(if triglycerides <3.39 mmol/l) or by ultracentrifugation. The LDL-Cholesterol/HDL-
Cholesterol, Total Cholesterol/HDL-Cholesterol and Triglycerides/HDL-Cholesterol ratios 
were calculated in all patients. Blood pressure and heart rate were measured in standard 
conditions. Ankle-Brachial index (ABI) was estimated bilaterally as the ratio of ankle (left 
and right) systolic blood pressure and brachial (highest upper limb) systolic blood pressure. 
The normal range for ABI was 0.9-1.3 mmHg, and individuals with ABI<0.9 were classified 
as having peripheral arterial disease. 
All data was processed using STATA for Windows, version 11.1. The distribution of the 
variables was tested for normality using the Kolmogorov-Smirnov test, and for 
homogeneity of variance by Levene’s test. Simple descriptive statistics were used to 
characterize the sample and the distribution of variables. Logistic regression analysis was 
used to determine the influence of the lipidic parameters on the occurrence of PAD.  
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Groups were compared using the χ2 test for categorical variables and the Student’s t test (2 
groups) or ANOVA with the post-hoc Tukey test (3 groups) for quantitative variables. A 
value of P≤0.05 was taken as the criterion of statistical significance for a 95% confidence 
interval. 
3.2.2 Results 
The general characteristics of the studied population are summarized in Table 4. Mean age 
was 64.23±12.30, with a similar proportion of men versus women (49% and 51%, 
respectively).  
 
 Total
(n=920) 
No PAD 
Patients 
(n=803) 
PAD 
Patients 
(n=117) 
p-value 
(PAD 
versus  
No PAD) 
Age, years  64.23±12.30 63.23±12.30 69.88±8.15 <0.01 
Sex, men:women 49:51 48:52 52:48 0.462 
Body Mass Index, Kg/m2 28.79±11.85 28.92±12.53 27.94±5.31 0.416 
CV events history, no:yes 88:12 90:10 75:25 <0.01 
Tobacco Consumption, 
no:yes  
89:11 89:11 88:12 0.856 
Dyslipidemia, no:yes 40:60 42:58 26:74 <0.01 
Diabetes, no:yes 66:34 68:32 54:46 <0.01 
SBP, mmHg  150.14±20.69 148.97±19.60 157.81±25.59 <0.01 
DBP, mmHg  86.28±10.91 86.59±10.63 84.20±12.43 0.025 
Heart Rate, bpm 70.52±10.48 69.12±9.42 71.22±9.21 0.791 
Plasma Glucose, mg/dl 112.42±39.65 111.35±39.10 119.61±42.60 0.035 
Plasma Creatinine, mg/dl 0.88±0.22 0.87±0.21 0.96±0.26 <0.01 
eGFR, ml/min/1.73m2 84.73±23.28 85.86±23.40 76.94±20.88 <0.01 
ABI 1.09±0.14 1.12±0.12 0.8±0.10 <0.01 
PAD – peripheral artery disease; CV – cardiovascular events; SBP – systolic blood pressure; DBP – 
diastolic blood pressure; eGFR – estimated Glomerular Filtration Rate; ABI – Ankle-Brachial Index 
Table 4. Characteristics of the study population, in general and stratified for the presence or 
absence of peripheral artery disease. 
Mean body mass index was 28.79±11.85, indicating an overwheighted population. With 
regard to cardiovascular risk factors, all patients were hypertensive, 60% had dyslipidemia 
and 34% were diabetic; 11% were smokers and 12% had a personal history of cardiovascular 
events (mainly Stroke). About 37% were medicated for cardiovascular pathologies, with 
13.6% of the patients undertaking statins. This factor was controlled in all the multivariable 
analysis. Peripheral artery disease (PAD) was encountered in 117 patients (12.7%). Patients 
with PAD were older, and had a worst metabolic and hemodynamic profile. The proportion 
of patients with a personal history of cardiovascular events was also greater in patients with 
PAD (25% versus 10%, p<0.01). The Ankle-Brachial Index (ABI) was also significantly lower 
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in patients with PAD, as expected. Interestingly, patients with PAD also had a significantly 
lower estimated glomerular filtration rate (76.94±20.88 ml/min/1.73m2 versus 85.86±23.40 
ml/min/1.73m2 in patients without PAD). 
Regarding the overall and the comparative lipidic profile (depicted in table 5), significant 
differences amongst patients with and without PAD were only observed for the three 
considered lipidic ratios, expressing higher values when PAD was present, and for the 
HDL-cholesterol, with the PAD patients reaching lower HDL levels (although tendencially, 
p-value=0.073). 
 
 Total 
(n=920) 
No PAD 
Patients 
(n=803) 
PAD 
Patients 
(n=117) 
p-value 
(PAD versus 
No PAD) 
Plasma Total Cholesterol, 
mg/dl  
196.61±41.15 197.06±41.18 193.68±40.98 0.400 
Plasma LDL-Cholesterol, 
mg/dl 
116.31±37.62 116.17±41.18 193.68±40.98 0.763 
Plasma HDL-Cholesterol, 
mg/dl 
54.46±21.47 54.96±21.56 51.14±20.65 0.073 
Plasma Triglicerides, 
mg/dl 
134.84±67.88 134.20±41.18 139.09±66.02 0.460 
LDL-Colesterol/HDL-
Colesterol Racio 
2.55±2.45 2.48±2.11 3.04±2.03 <0.01 
Total Cholesterol/HDL-
Colesterol Racio 
4.15±2.95 4.06±2.48 4.80±2.05 <0.01 
Triglicerídeos/HDL-
Colesterol Racio 
2.97±2.98 2.88±2.44 3.59±2.33 <0.01 
Table 5. Lipid profile of the study population. 
Figure 1 further ilustrates the differences in the lipidic ratios among patients with and 
without PAD, with all three considered ratios presenting significant differences between the 
considered groups. 
A multivariable logistic regression analysis was also performed considering PAD as the 
dependent variable (dichotomized in normal/abnormal), and forcing each lipidic parameter 
(either individual lipis or lipid ratios) in a model adjusted for the conventional Framingham 
cardiovascular risk factors (age, sex, diabetes, blood pressure, smoking status and body 
mass index). The observed Odds Ratios (OR) with 95% confidence intervals is depicted in 
figure 2. Although there’s an appreciable tendency of association with PAD in all lipid 
variables, it reaches statistical significancy only for the lipidic ratios. In fact, the OR for LDL-
cholesterol, Total-cholesterol, HDL-cholesterol and Triglycerides were respectively 1.004 
(IC: 0.999-1.010, p=0.1), 1.001 (IC: 0.996-1.007, p=0.4), 0.993 (IC: 0.980-1.004, p=0.2) and 1.001 
(IC: 0.998-1.004, p=0.2). For the LDL-cholesterol/HDL-cholesterol ratio, the multiadjusted 
OR was 1.06 (IC: 0.999-1.120, p=0.052), with a marginally significant association with PAD. 
For the Total-cholesterol/HDL-cholesterol and the Triglycerides/HDL-cholesterol ratios, 
the adjusted OR were respectively 1.051 (IC: 1.011-1.200, p=0.01) and 1.050 (IC: 1.002-1.110, 
p=0.04). A further analysis showed that the association of the lipid ratios with PAD was 
tendencially linear, particularly for the Total-cholesterol/HDL-cholesterol ratio. 
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PAD – peripheral artery disease 
Fig. 1. Representation of the comparative lipid ratios in patients with and without peripheral 
arterial disease. 
 
 
OR – Odds Ratio 
Fig. 2. Adjusted Odds Ratios for Peripheral Artery Disease for the individual lipidic 
variables and for the lipidic ratios. The Odds Ratios are multi-adjusted to conventional 
Framingham cardiovascular risk factors. 
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3.3 Study 2 – Usefulness of the lipidic ratios in a low-to-moderate cardiovascular risk 
population: A sub-analysis of the EDIVA (Estudo de Distensibilidade Vascular) project 
The EDIVA project was an epidemiological study assessing cardiovascular risk through 
sequential Pulse Wave Velocity measurement (Maldonado, Pereira, Polónia et al, 2011), but 
since serum lipids were available for all the included patients, we re-analyzed the EDIVA 
database aiming to address the delineated objective: to ascertain the usefulness of The LDL-
Cholesterol/HDL-Cholesterol, Total Cholesterol/HDL-Cholesterol and Triglycerides/HDL-
Cholesterol ratios in the general population. The study population consisted of 2200 
Portuguese nationals (1290 men and 910 women), aged between 18 and 91 years (mean 
46.33±13.76 years). Of these, 668 had low cardiovascular risk, and 1532 were patients with 
hypertension, diabetes and/or dyslipidemia. Individuals defined as having low 
cardiovascular risk were those who had had no chronic disease, had never been prescribed 
chronic pharmacological therapy, and had a normal physical exam, electrocardiogram, 
blood and urine tests, these characteristics having remained unchanged for at least two 
annual assessments. The patient group was under pharmacological therapy for at least one 
of the above pathologies. 
3.3.1 Methods 
The study’s aims were explained to all participants and their informed consent was 
obtained. The methodology used to collect the data was approved by the Portuguese Data 
Protection Commission and the study was approved by the Ethics Committees of the 
hospitals involved. Mean follow-up was 2 years. 
This was a prospective, multicenter, observational study monitoring the occurrence of major 
adverse cardiovascular events (MACE) – death, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, peripheral arterial disease, revascularization or renal failure. 
Follow-up of the patients consisted of annual assessments including, blood pressure (BP) 
measurement, laboratory tests, including serum lipids, and clinical observation. Total 
cholesterol, triglycerides and HDL cholesterol were measured. LDL cholesterol was 
obtained by Friedewald’s formula (if triglycerides <3.39 mmol/l) or by ultracentrifugation. 
The LDL-Cholesterol/HDL-Cholesterol, Total Cholesterol/HDL-Cholesterol and 
Triglycerides/HDL-Cholesterol ratios were calculated in all patients. At each consultation, 
the subjects’ weight and height were measured and body mass index (BMI) was calculated 
in kg/m2. Blood pressure and heart rate were measured in standard conditions, in a supine 
position and after a 10-minute resting period, by an experienced operator and using a 
clinically validated (class A) sphygmomanometer (Colson MAM BP 3AA1-2®; Colson, 
Paris) (Pereira & Maldonado, 2005).Three measurements were taken and the arithmetic 
mean was used in the analysis. All participants underwent routine fasting laboratory tests. 
At the first consultation they filled out a questionnaire concerning relevant personal and 
family history, smoking habits, alcohol consumption and medication. 
Data from the sample subjects were processed using STATA for Windows, version 11.1. The 
distribution of the variables was tested for normality using the Kolmogorov-Smirnov test, 
and for homogeneity of variance by Levene’s test. Simple descriptive statistics were used to 
characterize the sample and the distribution of variables. Cox proportional hazards analysis 
was used to determine the influence of the lipidic parameters on the occurrence of the 
specified cardiovascular events. C-Statistics was calculated to address the reliability of the 
lipidic parameters as prognostic variables.  
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Groups were compared using the χ2 test for categorical variables and the Student’s t test (2 
groups) or ANOVA with the post-hoc Tukey test (3 groups) for quantitative variables. A 
value of P≤0.05 was taken as the criterion of statistical significance for a 95% confidence 
interval. 
3.3.2 Results 
The general characteristics of the study population are summarized in Table 6. Mean age 
was 46.33±13.77, indicating a relatively young sample, with similar proportions of men and 
women (59% and 41%, respectively). With regard to cardiovascular risk factors, 52% of the 
patients were hypertensive, 33% had dyslipidemia and 11% were diabetic; 17% were 
smokers and 15% had a family history of cardiovascular events. About 37% were medicated 
for cardiovascular pathologies, with 13.6% of the patients undertaking statins. This factor 
was controlled in all the multivariable analysis. Mean follow-up is currently 21.42±10.76 
months. A total of 50 non-fatal MACE (2.2% of the sample) were recorded, including 27 
cases of stroke, 19 of coronary events, 2 of renal failure and 2 of occlusive peripheral arterial 
disease. 
 
 No MACE MACE  
 Total Low Risk 
Patients 
Patients Patients p-value 
(MACE  
vs  
No MACE) 
N,%  2200 32% 66% 2%  
Age, years  46.33±13.77 40.00±13.42 49.03±13,14 50.00±10,21 0.360 
Sex, men:women* 59:41 60:40 58:42 46:54 0.104 
Body Mass Index, 
Kg/m2  
27.18±5.50 25.90±4.21 27.71±4.45 28.59±5.75 0.348 
Waist, cm  89.82±11,05 86.83±10,30 90.63±11,00 90.00±13,06 0.917 
Family History, 
no:yes*  
85:15 92:8 83:17 60:40 0.020 
Tobacco Consumption, 
no:yes*  
83:17 78:22 85:15 78:22 0.243 
Hypertension, no:yes* 48:52 100:0 26:74 14:86 0.109 
Dyslipidemia, no:yes* 67:33 100:0 53:47 60:40 0.311 
Diabetes, no:yes* 89:11 100:0 85:15 86:14 0.941 
SBP, mmHg  142.51±21.05 129.17±14.33 147.83±14.33 161.08±17.34 <0.001 
DBP, mmHg  84.52±12.29 77.43±10.11 87.32±11.87 92.08±10.07 <0.001 
PP, mmHg  57.99±15.29 51.74±11.90 60.05±15.86 66.20±12.93 <0.001 
MAP, mmHg  103.85±14.02 94.68±1.26 107.48±13.52 117.14±11.43 <0.001 
Heart Rate, bpm 70.56±12.24 68.21±12.58 71.49±11.87 78.20±13.01 0.001 
Plasma Glucose, mg/dl 100.44±31.54 90.86±9.16 103.70±3.75 110.32±39.64 0.406 
Plasma Creatinine, 
mg/dl 
1.31±5.08 0.90±1.77 1.43±5.99 1.53±2.92 0.996 
MACE – major acute cardiovascular events; SBP – systolic blood pressure; DBP – diastolic blood 
pressure; PP – pulse pressure; MAP – mean blood pressure 
Table 6. General characteristics of the study cohort, depending on the presence of MACE 
and conventional cardiovascular risk factors. 
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Regarding the lipidic profile, patients with MACE presented higher levels of the different 
lipidic parameters, as illustrated in table 7, in particular the lipidic ratios were significantly 
higher in patients with MACE (5.76±1.74  versus 6.75±1.98 for Total Cholesterol/HDL-
Cholesterol ratio, 3.24±1.32 versus 4.51±1.49 for LDL-Cholesterol/HDL-Cholesterol ratio, 
3.17±1.34 versus 4.35±1.67 for Triglycerides/HDL-Cholesterol ratio, p-value<0.01). So, 
overall, the patients with MACE were characterized by an unfavorable metabolic profile 
compared to the asymptomatic patients.  
 
 No MACE 
(n=2150) 
MACE 
(n=50) 
p-value 
Plasma Total Cholesterol, mg/dl 221.37±34.01 238.43±36.12 <0,01 
Plasma LDL-Cholesterol, mg/dl 141.37±31.22 163.26±41.12 <0,01 
Plasma HDL-Cholesterol, mg/dl 41.22±11.07 36.19±7.28 <0,01 
Plasma Triglicerides, mg/dl 156.37±34.01 181.43±36.12 <0,01 
LDL-Colesterol/HDL-Colesterol Ratio 2.98±2.32 4.51±1.49 <0,01 
Total Cholesterol/HDL-Colesterol Ratio 4.76±2.11 6.75±1.98 <0,01 
Triglicerídeos/HDL-Colesterol Ratio 3.17±2.32 4.35±1.67 <0,01 
MACE – major acute cardiovascular events; SBP – systolic blood pressure; DBP – diastolic blood 
pressure; PP – pulse pressure; MAP – mean blood pressure 
Table 7. Lipid profile of the study cohort, stratified for the presence or absence of of MACE. 
In the multivariable model analysis, adjusting for all conventional Framingham 
cardiovascular risk factors (age, sex, diabetes, blood pressure, smoking status and body 
mass index), the lipids ratios were associated with MACE, with stronger associations than 
the ones observed for the individual lipidic variables. Overall, the Total-Cholesterol/HDL-
Cholesterol was found to be the best single predictor of MACE. In figure 3 we plot the 
hazard ratios for quintiles of the lipid ratios. A linear increase of the hazard ratios across 
quintiles of the Total-Cholesterol/HDL-Cholesterol is clearly depicted, while for the other 
ratios only the upper-extreme quintiles showed an important association with 
cardiovascular events. 
Comparative data of risk association for those in the extreme quintiles of each lipidic 
variable is presented in figure 4. Of note, one can see that the combination of two individual 
lipidic components into a single variable provides stronger association with cardiovascular 
risk, as expressed by the depicted hazard ratios for the lipid ratios. On the other hand, the 
lipid ratio with the strongest association was the Total-Cholesterol/HDL-Cholesterol ratio, 
in line with the data depicted in figure 3.  
The ROC curve analysis provided the Areas-Under-the-Curve (AUC, equivalent to the C-
statistics) for the different lipid parameter considered in the analysis. The parameters with 
the biggest AUC were the Total-cholesterol/HDL-cholesterol ratio (AUC=0.703, IC:0.65-
0.77) and the LDL-cholesterol/HDL-cholesterol (AUC=0.701, IC:0.64-0.79). 
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* p-value<0.01. 
Fig. 3. Adjusted Hazard Ratios for major acute cardiovascular events distributed according 
to quintiles of the lipid ratios. A) Hazard ratios for quintiles of the LDL-Cholesterol/HDL-
Cholesterol ratio; B) Hazard ratios for quintiles of the Triglycerides/HDL-Cholesterol ratio; 
C) Hazard ratios for quintiles of the Total-Cholesterol/HDL-Cholesterol ratio. The hazard 
ratios are multi-adjusted to conventional Framingham cardiovascular risk factors. 
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Fig. 4. Adjusted Hazard Ratios for major acute cardiovascular events amongst those in the 
extreme quintiles of each considered lipidic parameter. The hazard ratios are multi-adjusted 
to conventional Framingham cardiovascular risk factors. 
4. Discussion and conclusions 
As previously mentioned, cardiovascular disease, as an expression of atherosclerotic 
processes, is the leading cause of death in industrialized countries. The key role played by 
cholesterol in essential pathophysiologic processes that lead to the occurrence of clinically 
significant cardiovascular events is well recognized. In contemporary clinical practice, this 
notion is well entrenched, and the individual cardiovascular risk definition incorporates, 
among other factors, the lipid profile, including the Total Cholesterol, LDL Cholesterol, 
HDL Cholesterol and triglycerides. A practical evidence of the aforementioned is the fact 
that the major cardiovascular risk tables currently available (e.g. the Framingham score or 
the EuroSCORE), incorporate lipid parameters in the definition of thresholds of risk. On the 
other hand, therapeutic decisions and monitoring have been largely centered on the 
conventional lipid profile. Even the international recommendations (such as those issued by 
the National Cholesterol Education Program - NCEP, 2001) recommend target levels of LDL 
and HDL -cholesterol to determine cardiovascular risk and evaluate the effectiveness of 
lipid-lowering therapies. However, some studies have indicated important limitations of 
these parameters in the prediction of cardiovascular risk, particularly in patients with 
intermediate cardiovascular risk (Gotto, Whitney, Stein et al, 2000). 
However, more recent evidence has suggested other lipidic components to optimize the 
definition of cardiovascular risk in clinical practice. In fact, several studies have expressed 
the superiority of the levels of apolipoprotein (apo) B, apo A-1 and its ratio, both in 
predicting cardiovascular events and in the evaluation of treatment efficacy (Packard & 
Marcovina, 2006; Yusuf , Hawken, Ounpuu, et al, 2004; Meisinger, Loewel, Mraz et al, 2005; 
Barter, Ballantyne, Carmena et al, 2006; Kim, Chang, Choi et al, 2005). In fact, considering 
that each lipidic particle contains one molecule of the atherogenic apo B, then its levels are a 
direct measure of the number of potentially atherogenic particles in the different 
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conventional lipid components (Walldius & Junger, 2006). In contrast, the concentration of 
apo A-1 translates the number of anti-atherogenic particles contained in the HDL-
cholesterol, thus enclosing the conceptual framework of apoB/apoA-1 ratio as a measure of 
the ratio of atherogenic particles versus anti-atherogenic particles transported in the blood. 
Despite the growing enthusiasm about the potential of these emerging parameters for their 
best performance in the definition of cardiovascular risk, there still remain some questions 
that limit their dissemination in clinical practice. The central question is very practical, and 
focuses on the cost-benefit relation associated with a change in the traditional clinical 
approach. In fact, it is not yet clear whether the superiority of these new lipid parameters 
over the more conventional ones for risk stratification is enough to justify the additional cost 
inherent to their laboratory determination (Pischon, Girman, Sacks et al, 2005). Furthermore, 
despite the current literature supporting apolipoproteins as better predictors of 
cardiovascular events, its use may not be the most practical operational perspective. 
Moreover, it is not yet clear whether the replacement of conventional parameters for 
emerging ones will translate into clear clinical benefit, or if, conversely, it will confuse the 
various protagonists over the clinical decision frame. 
In contrast to this line of argument, several studies have also emerged affirming quite 
clearly the advantages of using lipid ratios, based on conventional parameters, such as those 
studied in this work. This is based on the fact that, on the one hand, they add cardiovascular 
risk discriminative capacity to the individual lipid parameters, and on the other, they are 
more favorable than the apolipoproteins considering cost and immediate operationalization 
(Gotto, Whitney & Stein, 2000). As mentioned earlier, several studies have shown fairly 
consistently that changes in these ratios are favorable indicators of cardiovascular disease 
risk, above the absolute levels of individual lipids (Natarajan, Glick, Criqui et al, 2003; 
Kannel, 2005). Accumulating evidence in this regard is quite broad, spreading over several 
clinical frameworks (Manninen, Tenkanen, Koskinen et al, 1992; Kannel, 2005; Cullen, 
Schulte, Assmann et al, 1997; Stampfer, Sacks, Salvini et al, 1991; Gaziano, Hennekens, 
O'Donnell et al, 1997; Packard, Ford, Robertson et al, 2005). The results presented here clearly 
fall into this line, reinforcing the belief in the superiority of the lipid ratios, particularly the 
Total-Cholesterol/HDL-Cholesterol and the LDL-Cholesterol/HDL-Cholesterol ratios, over 
the classic lipid parameters, predicting peripheral arterial disease in hypertensive patients 
(in a high cardiovascular risk) and predicting future major cardiovascular events (including 
stroke and myocardial infarction) in a low-to-intermediate cardiovascular risk population. 
One of the curious aspects extracted from the second presented study was the existence of a 
linear relationship for the Total-Cholesterol/HDL-Cholesterol ratio with the risk of MACE, 
something not apparent in the LDL-Cholesterol/HDL-Cholesterol ratio. This same result 
was reproduced in the Quebec Cardiovascular Study, in which more than 2.000 middle-
aged men were followed for 5 years, monitoring the occurrence of major cardiovascular 
events (Lemieux, Lamarche, Couillard et al, 2001). The lipid parameters with better 
performance in predicting risk in this study were the Total-Cholesterol/HDL-Cholesterol 
ratio and the LDL-Cholesterol/HDL-Cholesterol ratio, although only the first stated ratio 
expressed a linear relationship with risk. One possible explenation for this result is 
metabolic in nature. In fact, it is well documented that patients with dyslipidemia showing 
high triglycerides and low HDL-cholesterol (generally patients with abdominal obesity and 
insulin resistance), often have marginal or even normal levels of LDL-Cholesterol 
(Lamarche, Després, Moorjani et al, 1996). Moreover, LDL-Cholesterol concentrations are 
often estimated indirectly from 3 measurements (Total-Cholesterol, Triglycerides and HDL-
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Cholesterol), which may include a variation that can reach 25% (Schectman & Sasse, 1993), 
with a potential and quite significant impact in the LDL-Cholesterol/HDL-Cholesterol ratio, 
eventually under-estimated. By contrast, the two components included in the Total-
Cholesterol/HDL-Cholesterol ratio are measured directly. Supporting the superiority of 
these ratios over the isolated lipid parameters, is their unique ability to reflect the 
bidirectional cholesterol traffic (in and outward) through the arterial intima in a way that 
the individual LDL and HDL-Cholesterol levels cannot reach (Kannel, 2005). Consistent 
with this assumption, another recent cohort prospective study, involving over 15.000 
women followed over a period of 10 years, demonstrated that the Total-Cholesterol/HDL-
Cholesterol ratio alongside the non-HDL Cholesterol were predictors of future 
cardiovascular events, as good or better than apolipoprotein fractions (Ridker, Rifai, Cook et 
al, 2005). 
Of course, there are still unresolved issues, such as the definition of a cut-off in these ratios 
from which lipid-lowering therapy should be considered. The current guidelines of the 
NCEP (2001) recommend a cut-off of 2.5 for the ratio LDL-cholesterol/HDL-cholesterol. 
However, recent studies suggest that the risk of cardiovascular events begins to have 
significant expression for values between 3.3-3.7 (Cullen, Assmann & Schulte, 1997), in line 
with the results we reported here. 
Given all the data currently available, as long as the fundamental reservations to the routine 
use of apolipoproteins are not exceeded, the use of lipid ratios in clinical practice is strongly 
advised, both in risk stratification and therapeutic decision and in monitoring its 
effectiveness. 
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